Dato-DXd
Breast Cancer
TROPION-Breast05: A randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer
Schmid P, Oliveira M, O'Shaughnessy J, et al.
Ther Adv Med Oncol. 2025 Apr;17:17588359251327992. doi: 10.1177/17588359251327992.
T-DXd
Breast Cancer
Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: Results from the randomized DESTINY-Breast06 trial
Hu X, Curigliano G, Yonemori K, et al.
ESMO Open. 2025 May 14; 105082. doi: 10.1016/j.esmoop.2025.105082. Epub ahead of print
Valemetostat
Hematology
Effect of mild to moderate hepatic impairment on valemetostat pharmacokinetics: An open-label, phase I study
Tachibana M, Craveiro TV, Marbury TC, et al.
Clin Pharmacol Drug Dev. 2025 May 14. doi: 10.1002/cpdd.1544. Epub ahead of print.
T-DXd
Breast Cancer
Patient-reported outcomes from DESTINY-Breast04: Trastuzumab deruxtecan versus physician’s choice of chemotherapy in patients with HER2-low mBC
Ueno NT, Cottone F, Dunton K, et al.
Oncologist. 2025 May 8;30(5):oyaf048. doi: 10.1093/oncolo/oyaf048.
Quizartinib
Hematology
Synergistic activity of combined FLT3-ITD and MDM2 inhibition with quizartinib and milademetan in FLT3-ITD mutant/TP53 wild type acute myeloid leukemias
Zhang W, Li L, Muftuoglu M, et al.
Clin Cancer Res. 2025 May. doi: 10.1158/1078-0432.CCR-24-2764. Epub ahead of print.
T-DXd
Gastric Cancer
A multicenter randomized open-label phase 2 study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan: The EN-hance study
Aoyama T, Ooki A, Oba K, et al.
Int J Clin Oncol. 2025 Jun;30(6):1162-1173. doi: 10.1007/s10147-025-02748-8.
Edoxaban
Cardiovascular - AF
Effectiveness and safety of edoxaban in the routine clinical care of atrial fibrillation patients in Brazil: Prospective 1-year follow-up study – EdoBRA
Precoma DB, da Silva RP, Passos LCS, et al.
Arq Bras Cardiol. 2025 Apr;122(4):e20240589. Portuguese, English. doi: 10.36660/abc.20240589.
HER3-DXd
Lung Cancer
Other/Multi
Exposure–response relationships in patients with non-small-cell lung cancer and other solid tumors treated with patritumab deruxtecan (HER3-DXd)
Li L, Lee M, Joshi R, et al.
Clin Pharmacol Ther. 2025;118(2):408-417. doi: 10.1002/cpt.3674.
Valemetostat
Hematology
Pharmacokinetics, metabolism, and excretion of [14C]-valemetostat in healthy male participants, and in vitro plasma protein binding
Tachibana M, Siebers N, Craveiro TV, et al.
Cancer Chemother Pharmacol. 2025 Apr;95(1):54. doi: 10.1007/s00280-025-04771-y.
Pexidartinib
Other/Multi
Patient-reported continued benefits of pexidartinib for tenosynovial giant cell tumor based on a real-world study in the United States
Dai D, Pan I, Freivogel K, Ye X, Tecson K, Tap W
Oncologist. 2025 Mar;30(3):oyaf028. doi: 10.1093/oncolo/oyaf028.
